Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
991.55
+4.28 (+0.43%)
Streaming Delayed Price
Updated: 12:59 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
30
31
32
33
34
35
36
37
Next >
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
October 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine...
Via
Benzinga
Exposures
Product Safety
Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters
October 18, 2021
Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a...
Via
Benzinga
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
October 18, 2021
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral...
Via
Talk Markets
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
October 18, 2021
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....
Via
Benzinga
Exposures
Product Safety
3 No-Brainer Biotech Stocks to Buy Right Now
October 16, 2021
Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Viatris should have plenty of room to run.
Via
The Motley Fool
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
October 15, 2021
Companies working on sorely needed Covid treatments are innovating to keep up.
Via
Investor's Business Daily
2 Cheap Growth Stocks That Could Be Even Better Buys in November
October 15, 2021
Both of these companies are reporting earnings within the next month, and there could be a dip in price that follows.
Via
The Motley Fool
Why Regeneron Shares Are Rising Today
October 14, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is trading higher Thursday after the company announced the FDA accepted for priority review a Biologics License Application for...
Via
Benzinga
Exposures
Product Safety
Expert Ratings For Regeneron Pharmaceuticals
October 12, 2021
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has obser...
Via
Benzinga
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
October 11, 2021
AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease...
Via
Benzinga
Exposures
COVID-19
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
October 11, 2021
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – With the arrival of the COVID-19 virus, the antivirals market had all eyes watching the ongoing frenetic rush to find a cure...
Via
FinancialNewsMedia
Exposures
COVID-19
Regeneron Could Have a Big Catalyst Coming in 2022
October 09, 2021
Cancer drug Libtayo could receive FDA approval for its fourth indication in January.
Via
The Motley Fool
Exposures
Product Safety
Cramer Likes DraftKings, Skyworks, And These Automakers
October 07, 2021
On CNBC's "Mad Money Lightning Rou...
Via
Benzinga
Tesla and Merck Give Investors Some Hope
October 04, 2021
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
Why Moderna, Novavax And Other COVID-19 Vaccine Stocks Are Plummeting
October 01, 2021
The COVID-19 pandemic proved to be a boon for many biopharma companies that benefited from their foray into the development of vaccines and/or treatments against the novel...
Via
Benzinga
Exposures
COVID-19
Merck Stock Surges Into Buy Zone As Covid Pill Reduces Risk Of Death, Hospitalization
October 01, 2021
Merck said its Covid pill, molnupiravir, cut the risk of death and hospitalization by half.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
September 30, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG (OTC: RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (...
Via
Benzinga
Exposures
COVID-19
Graybug Vision Posts Six-Month Extension GB-102 Data Of Wet AMD Trial
September 28, 2021
Graybug Vision Inc (NASDAQ: GRAY) has provided a full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD)....
Via
Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...
Via
Benzinga
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
September 27, 2021
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19...
Via
Benzinga
WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access
September 24, 2021
The World Health Organization (WHO) has supported another COVID-19 therapeutic but urged the related companies and governments to address the high price and limited...
Via
Benzinga
Exposures
COVID-19
Ligand Pharmaceuticals Stock Shows Rising Price Performance
September 22, 2021
A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance.
Via
Investor's Business Daily
Acceleron Pharma Stock Meets 80-Plus Relative Strength Rating Benchmark
September 22, 2021
Want to build a watch list? Focus on stocks with an 80-plus RS Rating. Acceleron Pharma stock cleared that benchmark with an upgrade to 83.
Via
Investor's Business Daily
Inmune Bio Stock Flashes Robust RS Rating
September 22, 2021
On Wednesday, Inmune Bio stock saw its Relative Strength Rating jump into the 90-plus percentile, to 92 from 85 the day before.
Via
Investor's Business Daily
Where to Invest $100 Right Now
September 22, 2021
These choices may surprise you.
Via
The Motley Fool
3 COVID Stocks to Buy in a Bear Market
September 21, 2021
If COVID-19 shocks the market again, our trio of Fools suggest that you might want to own shares of Moderna, Regeneron, and Figs.
Via
The Motley Fool
Exposures
COVID-19
I-Mab Stock Joins Rank Of Stocks With RS Ratings Over 90
September 20, 2021
Looking for the best stocks to buy? Focus on those with rising relative strength such as I-Mab stock, which saw a (RS) Rating upgrade to 93.
Via
Investor's Business Daily
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
September 20, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. ...
Via
Benzinga
AbbVie's Pain Is Sanofi's and Regeneron's Gain
September 18, 2021
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.
Via
The Motley Fool
Exposures
Product Safety
< Previous
1
2
...
30
31
32
33
34
35
36
37
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.